E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.15 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release film-coated tablet) and to collect supplementary data regarding the ovulation inhibitory effect of the well-established COC Valette SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest). The intended indication for the product under development is the hormonal contraception. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10030970 |
E.1.2 | Term | Oral contraception |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release film-coated tablet) and to collect supplementary data regarding the ovulation inhibitory effect of SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest) in treatment cycle 2. Ovulation inhibition will be assessed by TVU of the leading follicle diameter and by analysis of serum hormone levels (estradiol, progesterone). Ovarian activity will be classified according to Hoogland & Skouby (1993). A score of < 6 will be regarded as inhibition of ovulation. |
|
E.2.2 | Secondary objectives of the trial |
- Grading of ovarian activity according to Hoogland & Skouby (1993) - Follicle size (leading follicle) - Endogenous hormones (estradiol, progesterone, FSH, LH) - Assessment of cervical mucus according to Insler (1972) - Levels of DHEA-S, SHBG, and testosterone (only in volunteers receiving SH D00659AF) - Pharmacokinetic evaluation at steady-state (only in volunteers receiving the test product SH T04769G) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- healthy female volunteers aged between 18 and 35 years (inclusive), smokers not older than 30 years (inclusive) at inclusion - follicular diameter >= 15 mm before Visit 6 / admission to treatment or observed ovulation during pre-treatment cycle, absence of premature follicular ripening - non-suspicious cervical smear taken at Screening - signed and dated informed consent |
|
E.4 | Principal exclusion criteria |
- Pregnancy, lactation (less than 3 cycles following delivery, abortion, or lactation before start of pre-treatment cycle) - Known hypersensitivity to any ingredients of the study medication, e.g. patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption - Any known diseases or conditions that compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication - Any known severe systemic disease that might interfere with the conduct of the study or the interpretation of the results - Uncontrolled thyroid disorders - Clinically significant depression (current or in the last year) - Abnormal, clinically significant findings which, according to the assessment of the investigator, may worsen under hormonal treatment (e.g., pemphigoid gestationis during a previous pregnancy; middle-ear deafness (otosclerosis); sydenham chorea, porphyria, systemic lupus erythematodes, hemolytic uremic syndrome) - Laboratory values outside inclusion range at Screening - Participation in another clinical study or administration of an investigational drug within 1 month prior to study entry (Visit 1) - Operations scheduled in the study period - Liver diseases: acute and chronic progressive liver diseases, e.g., disturbances of the bilirubin excretion of the bile (Dubin-Johnson and Rotor syndromes) , disturbances of the bile secretion, disturbances in the bile flow, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment. Presence or history of liver tumors (benign or malignant) Existing or previous hepatic disease as long as liver function values have not returned to normal. There should be an interval of at least 3 months between the start of study medication intake and the return of liver function values to normal. - Pancreatitis or a history thereof if associated with severe hypertriglyceridemia - Vascular diseases and coagulation disorders: Existing or previous venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), existing or previous arterial thromboembolic diseases (myocardial infarction, stroke), presence or history of prodromi of a thrombosis (e.g., transient ischemic attack, angina pectoris), existing or previous cerebrovascular accident, as well as any condition that could increase the risk of any of the above, e.g., hereditary or acquired predisposition for venous or arterial thrombosis, such as APC-resistance, Antithrombin III (AT-III) deficiency, Protein-C and/or Protein-S deficiency, hyperhomocysteinemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant), any venous thromboembolic event that occurred in a close relative at a younger age (≤ 50 years), specific heart diseases (e.g., valvular heart disease, atrial fibrillation) cardiac dysfunction (NYHA I-IV), pronounced varicosis veins, mild varicosis veins or previous phlebitis in combination with other risk factors - Uncontrolled arterial hypertension (confirmed systolic blood pressure > 140 mmHg or confirmed diastolic blood pressure > 90 mmHg) - Known diabetes mellitus - Sickle-cell anemia - Known severe disturbances of lipid metabolism - Known or suspected malignant or premalignant steroid-hormone dependent diseases (e.g., endometrial cancer, breast cancer), also a history thereof. Volunteers with other malignancies / premalignancies may be included if they have been recurrence-free for at least 5 years. - Other diseases: migraine with neurologic symptoms (complicated migraine), undiagnosed vaginal bleeding, manifest kidney disease with impaired renal function, worsening of epilepsy or chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) under hormonal treatment - Alcohol, drug, or medicine abuse (e.g., laxatives) - Prohibited concomitant medication: Additional sex steroids (excluding topical use of Progestogel®); antiepileptics, hypnotics and sedatives; tuberculostatics; oral antimycotics; HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors; modafinil, cyclosporine, lamotrigine; products containing the herbal remedy St. John's wort (Hypericum perforatum); and continuous systemic use of antibiotics - Sex hormones prior to start of treatment: Oral, transdermal, intrauterine, or intravaginal administration within 1 cycle prior to start of pre-treatment cycle Use of implants within 1 month prior to Visit 1 Use of long-acting progestins within 6 months prior to Visit 1 - Use of intrauterine devices without hormone release within1 cycle prior to start of treatment. - Considerable overweight (body mass index > 30) - Volunteer is a dependent person, e.g., a relative, family member, or member of the investigator’s staff. - Volunteer is in custody by order of an authority or a court of law |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable of this study is ovulation inhibition in Treatment Cycle 2 (no/yes), as assessed by ultrasonographic monitoring (TVU) of the leading follicle diameter, and by analysis of serum hormone levels (estradiol, progesterone). Ovarian activity will be classified according to Hoogland & Skouby (1993). A score of < 6 will be regarded as inhibition of ovulation. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For a single volunteer, the study will be concluded on the day of her last visit (including last additional visit, if applicable) provided the results of the safety laoratory tests are available, evaluable, and consistent with the criteria defined. In other cases, the test has to be repeated, postponing therefore the End of Study. For the whole study, the End of Study is defined as last-volunteer-last-visit (including last additional visit, if applicable). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |